Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody,...

PreciseDx: In a collaboration with The Michael J. Fox Foundation, de novo study finds PreciseDx's technology can accurately diagnose Parkinson's disease in living patients prior to severe onset of symptoms NEW YORK, April 20,...

Researcher Christina Caira reflects on use of AI in Parkinson’s Disease research Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the degeneration of dopamine releasing regions in the brain....

Fimmic invites ECDP 2018 participants to attend our pre-conference symposium on Tuesday May 29, 2-4 PM at Hotel Clarion in Helsinki, Finland. The first part of our 2-hour symposium will feature customer presenters discussing how they are...